Barriers to Herpes Zoster Vaccination
Authors: Wim Opstelten
Journal: Annals of Internal Medicine (2010)

Letters21 September 2010Barriers to Herpes Zoster VaccinationWim Opstelten, MD, PhD, Gerrit A. van Essen, MD, PhD, and Eelko Hak, MSc, PhDWim Opstelten, MD, PhDFrom University Medical Center Utrecht, 3584CX Utrecht, the Netherlands; and University of Groningen, 9713 AV Groningen, the Netherlands., Gerrit A. van Essen, MD, PhDFrom University Medical Center Utrecht, 3584CX Utrecht, the Netherlands; and University of Groningen, 9713 AV Groningen, the Netherlands., and Eelko Hak, MSc, PhDFrom University Medical Center Utrecht, 3584CX Utrecht, the Netherlands; and University of Groningen, 9713 AV Groningen, the Netherlands.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-153-6-201009210-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Hurley and colleagues (1) showed that the major barriers that keep physicians from using the herpes zoster vaccine are the cost concerns of their patients and their own worries about freezer storage of the vaccine. These barriers may have resulted in low vaccine uptake. With respect to these findings, we would like to make some comments based on our prospective questionnaire study in the Netherlands (2). In our primary care study, we assessed the willingness of elderly patients to accept free herpes zoster vaccination simultaneously with their annual influenza vaccination. The participating primary care physicians were equipped ...References1. Hurley LP, Lindley MC, Harpaz R, Stokley S, Daley MF, Crane LA, et al. Barriers to the use of herpes zoster vaccine. Ann Intern Med. 2010;152:555-60. [PMID: 20439573] LinkGoogle Scholar2. Opstelten W, van Essen GA, Hak E. Determinants of non-compliance with herpes zoster vaccination in the community-dwelling elderly. Vaccine. 2009;27:192-6. [PMID: 18996427] CrossrefMedlineGoogle Scholar3. Gilderman LI, Lawless JF, Nolen TM, Sterling T, Rutledge RZ, Fernsler DA, et al; Zostavax Protocol 010 Study Group. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clin Vaccine Immunol. 2008;15:314-9. [PMID: 18077611] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University Medical Center Utrecht, 3584CX Utrecht, the Netherlands; and University of Groningen, 9713 AV Groningen, the Netherlands.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoBarriers to the Use of Herpes Zoster Vaccine Laura P. Hurley , Megan C. Lindley , Rafael Harpaz , Shannon Stokley , Matthew F. Daley , Lori A. Crane , Fran Dong , Brenda L. Beaty , Litjen Tan , Christine Babbel , L. Miriam Dickinson , and Allison Kempe Barriers to Herpes Zoster Vaccination Laura Hurley and Allison Kempe Metrics Cited ByProviders' lack of knowledge about herpes zoster in HIV-infected patients is among barriers to herpes zoster vaccination 21 September 2010Volume 153, Issue 6Page: 418KeywordsConflicts of interestElderlyPerceptionProspective studiesQuestionnairesTemperatureVaccines ePublished: 21 September 2010 Issue Published: 21 September 2010 CopyrightCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...